Aim: To retrospectively assess the effectiveness and safety of BLES stereotactic biopsy of suspicious calcifications and investigate possible predictive factors for underestimation.
Methods And Materials: Between January 2014 and January 2016, 400 biopsies of suspicious calcifications were performed in our Department using the BLES stereotactic device. The mean age of our population was 58.5 years (range 39-78 years). The final surgical results were used as gold standard. The effectiveness of the method was statistically evaluated. Mammographic size, grade, molecular type, and presence of comedo type/necrosis were assessed as predictive factors.
Results: 90/400 (22.5%) cases were cancers (20% invasive cancers, 80% non-invasive cancers). 38/400 cases were atypical lesions (9.5%). No underestimation was found in atypical lesions that underwent surgery (29/38 cases). Downgrade was achieved in 45.5% of cases (with complete removal in 34.4%), concordance in 43.3%, and upgrade was found in 15.5% of the cases; the initial mammographic size and the grade of the cancers were found to be statistically significant predictive factors. The total complication rate was 8.75%.
Conclusions: Breast lesion excision system is a highly accurate and safe stereotactic biopsy technique of suspicious calcifications with low underestimations and high downgrade/removal rates with the potential to alter the final surgical decision in selected cases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/tbj.13513 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mammographic Vascular Microcalcifications as a Surrogate Parameter for Coronary Heart Disease: Correlation to Cardiac Computer Tomography and Proposal of a Classification Score.
Diagnostics (Basel)
December 2024
Institute of Diagnostic and Interventional Radiology, GZO Regional Health Center, 8620 Wetzikon, Switzerland.
Objective: This study develops a BI-RADS-like scoring system for vascular microcalcifications in mammographies, correlating breast arterial calcification (BAC) in a mammography with coronary artery calcification (CAC), and specifying differences between microcalcifications caused by BAC and microcalcifications potentially associated with malignant disease.
Materials And Methods: This retrospective single-center cohort study evaluated 124 consecutive female patients (with a median age of 57 years). The presence of CAC was evaluated based on the Agatston score obtained from non-enhanced coronary computed tomography, and the calcifications detected in the mammography were graded on a four-point Likert scale, with the following criteria: (1) no visible or sporadically scattered microcalcifications, (2) suspicious microcalcification not distinguishable from breast arterial calcification, (3) minor breast artery calcifications, and (4) major breast artery calcifications.
Imaging Characteristics of Primary Mucinous Cystadenocarcinoma of the Breast: A Case Report and Literature Review.
Curr Med Imaging
January 2025
Department of Pathology, Affiliated Jinhua Hospital Zhejiang University School of Medicine, Jinhua, Zhejiang, 32100, P. R. China.
Introduction: Mucinous Cystadenocarcinoma (MCA) of the breast remains a relatively rare condition, and to date, there is no systematic summary of its imaging manifestations. Therefore, this report presents a detailed account of the diagnosis and treatment of mucinous cystadenocarcinoma in a 40-year-old woman, with a particular focus on imaging findings. Additionally, we conducted a comprehensive literature review on this disease and summarized its key imaging features.
View Article and Find Full Text PDFA Unique Case of Infected Laryngeal Tophi With Underlying Gout.
Cureus
November 2024
Otolaryngology - Head and Neck Surgery, Hospital Queen Elizabeth, Kota Kinabalu, MYS.
Gout is a disorder of purine metabolism described by the deposition of monosodium urate crystals with rare involvement in the head and neck. This is the first laryngeal gout case reported in Sabah, Malaysia. A 50-year-old gentleman with a long history of gouty arthritis presented with acute painless anterior neck swelling for two weeks.
View Article and Find Full Text PDFUnderstanding BI-RADS Category 3.
Radiographics
January 2025
From the Department of Radiology, Division of Breast Imaging, UC San Diego Health, Koman Family Outpatient Pavilion, 9400 Campus Point Dr, #7316, La Jolla, CA 92037 (S.F., J.S., R.R.P., H.O.F.); and Department of Breast Imaging, Division of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, Tex (M.S.G., B.A.).
Article Synopsis
- The BI-RADS category 3 assessment indicates findings that are "probably benign," with a less than 2% chance of being cancerous, helping to reduce unnecessary breast biopsies.
- Despite its established guidelines for mammography, breast ultrasound, and emerging MRI uses, there is still confusion and misuse surrounding this category.
- Category 3 findings should be followed up with short-term imaging to monitor for changes, and it is not appropriate to use in screening studies without further diagnostic evaluations.
Machine Learning Based on Digital Mammography to Reduce the Need for Invasive Biopsies of Benign Calcifications Classified in BI-RADS Category 4.
J Imaging Inform Med
December 2024
Department of Radiology, Tongde Hospital of Zhejiang Province, No. 234, Gucui RoadZhejiang Province, Hangzhou, 310012, China.
This study aims to develop a machine learning model applied on digital mammograms to reduce unnecessary invasive biopsies for suspicious calcifications classified as BI-RADS category 4. This study retrospectively analyzed data from 372 female patients with pathologically confirmed BI-RADS category 4 mammographic calcifications. Patients from the First Affiliated Hospital of Bengbu Medical College (n = 275) were divided chronologically into a training and internal validation set.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!